Maria Chaudhry, MD
The Ohio State University, The James Cancer Center
Interview Date: September 13, 2018
A new drug by GlaxoSmithKlein drew attention at last year's American Society of Hematology (ASH) meeting for multiple myeloma patients. Learn more about this antibody drug conjugate which carries a toxic load directly to myeloma cells using the BCMA target. Dr. Chaudhry shares the outcomes of the first Phase I clinical trial and the opening of the Phase II study. The GSK drug targets the common BCMA protein found on the surface of myeloma cells and in the Phase I study, the drug was used alone with strong results, even for patients who had relapsed after common myeloma therapies like Velcade, Revlimid and daratumumab (Darzalex). A Phase II study is now underway. Learn more about how the drug works and what is involved in participating.
Thanks to our episode sponsor, Celgene Corporation.
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113